Susceptibilities of Clinical and Laboratory Isolates of Blastomyces dermatitidis to Ketoconazole, Itraconazole, and Fluconazole
- 1 April 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (4) , 978-980
- https://doi.org/10.1128/aac.42.4.978
Abstract
Eighteen isolates of Blastomyces dermatitidis were evaluated for their in vitro susceptibilities to ketoconazole, itraconazole, and fluconazole. The MIC ranges were 0.1 to 0.4 μg/ml for ketoconazole, ≤0.018 to 0.07 μg/ml for itraconazole, and 2.5 to 4.0 μg/ml for fluconazole. The ranges for the minimal lethal concentrations were 0.2 to 0.8 μg/ml for ketoconazole, ≤0.018 to 0.07 μg/ml for itraconazole, and 10 to 40 μg/ml for fluconazole. Itraconazole was the most active agent against B. dermatitidis in vitro, while fluconazole was the least active. These results correlate with the clinical efficacies noted to date with doses of these agents used to treat blastomycosis.Keywords
This publication has 17 references indexed in Scilit:
- Treatment of Blastomycosis with Higher Doses of FluconazoleClinical Infectious Diseases, 1997
- Histoplasmosis and BlastomycosisClinical Infectious Diseases, 1996
- High-Dose Fluconazole Therapy for Cryptococcal Meningitis in Patients with AIDSClinical Infectious Diseases, 1996
- Treatment of Blastomycosis with Fluconazole: A Pilot StudyClinical Infectious Diseases, 1995
- Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratoriesDiagnostic Microbiology and Infectious Disease, 1994
- Itraconazole therapy for blastomycosis and histoplasmosisThe American Journal of Medicine, 1992
- Treatment of Coccidioidal Meningitis with FluconazoleClinical Infectious Diseases, 1990
- Treatment of Mycoses with ItraconazoleAnnals of the New York Academy of Sciences, 1988
- Pharmacology and toxicity of high-dose ketoconazoleAntimicrobial Agents and Chemotherapy, 1987
- Initial Experience in Therapy for Progressive Mycoses with Itraconazole, the First Clinically Studied TriazoleClinical Infectious Diseases, 1987